OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL raised its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 177.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,486 shares of the company's stock after purchasing an additional 42,526 shares during the period. Tudor Investment Corp ET AL owned 0.27% of OrthoPediatrics worth $1,541,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Barclays PLC grew its holdings in shares of OrthoPediatrics by 319.3% during the third quarter. Barclays PLC now owns 25,298 shares of the company's stock worth $686,000 after buying an additional 19,264 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in OrthoPediatrics by 1.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 251,588 shares of the company's stock valued at $5,832,000 after buying an additional 4,728 shares during the last quarter. R Squared Ltd acquired a new stake in OrthoPediatrics in the 4th quarter valued at approximately $48,000. Rhumbline Advisers lifted its stake in OrthoPediatrics by 4.1% during the 4th quarter. Rhumbline Advisers now owns 26,411 shares of the company's stock worth $612,000 after acquiring an additional 1,042 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in OrthoPediatrics in the 4th quarter valued at about $171,000. Institutional investors and hedge funds own 69.05% of the company's stock.

OrthoPediatrics Price Performance

NASDAQ:KIDS traded up $0.81 during trading hours on Wednesday, hitting $22.21. The company's stock had a trading volume of 259,527 shares, compared to its average volume of 196,433. OrthoPediatrics Corp. has a 52-week low of $20.25 and a 52-week high of $35.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The business's 50-day moving average is $23.10 and its two-hundred day moving average is $24.14. The company has a market capitalization of $539.29 million, a PE ratio of -18.05 and a beta of 1.09.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.01). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. As a group, research analysts anticipate that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Insider Buying and Selling

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $164,573.20. Following the transaction, the chief executive officer now directly owns 319,155 shares of the company's stock, valued at $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Fred Hite sold 6,443 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $160,172.98. Following the completion of the transaction, the chief financial officer now owns 207,989 shares in the company, valued at $5,170,606.54. This represents a 3.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,732 shares of company stock worth $589,978. 32.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Lake Street Capital began coverage on OrthoPediatrics in a research note on Monday, April 7th. They issued a "buy" rating and a $37.00 price target on the stock. Truist Financial cut their target price on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Stifel Nicolaus dropped their price target on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, April 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $37.00.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.